13.3 Modern Contraceptive Technology & WHO MEC Criteria

Modern Contraceptive Technology & WHO MEC Criteria

Family planning is a cornerstone of maternal, neonatal, and child health in Kenya. Modern contraceptive technology directly prevents unintended pregnancies, reduces maternal morbidity and mortality by over 30%, eliminates unsafe abortions, and promotes child survival through healthy birth spacing. In clinical practice and licensure examinations conducted by the Clinical Officers Council (COC), clinical officers must possess a sophisticated command of the World Health Organization (WHO) Medical Eligibility Criteria (MEC) to match clients with safe, effective, and acceptable contraceptive methods based on underlying medical conditions and reproductive goals.

---

1. The WHO Medical Eligibility Criteria (MEC) Framework

The WHO Medical Eligibility Criteria for Contraceptive Use provides an evidence-based clinical decision-making framework, classifying client conditions into four safety categories:

WHO MEDICAL ELIGIBILITY CRITERIA (MEC) CLASSIFICATION:

┌────────────┬─────────────────────────────────────────────────────────────┬──────────────────────────┐
│ Category   │ Clinical Definition / Risk Assessment                       │ Practical Clinical Action│
├────────────┼─────────────────────────────────────────────────────────────┼──────────────────────────┤
│ Category 1 │ A condition for which there is NO RESTRICTION for the use    │ Use method in any        │
│            │ of the contraceptive method.                                │ circumstances.           │
├────────────┼─────────────────────────────────────────────────────────────┼──────────────────────────┤
│ Category 2 │ A condition where the ADVANTAGES of using the method         │ Method generally CAN be  │
│            │ GENERALLY OUTWEIGH the theoretical or proven risks.         │ used; routine follow-up. │
├────────────┼─────────────────────────────────────────────────────────────┼──────────────────────────┤
│ Category 3 │ A condition where the THEORETICAL OR PROVEN RISKS USUALLY   │ Method NOT recommended   │
│            │ OUTWEIGH the advantages of using the method.                │ unless other methods are │
│            │                                                             │ unavailable/unacceptable.│
├────────────┼─────────────────────────────────────────────────────────────┼──────────────────────────┤
│ Category 4 │ A condition which represents an UNACCEPTABLE HEALTH RISK   │ Method MUST NOT be used  │
│            │ if the contraceptive method is used.                        │ (Strict Contraindication)│
└────────────┴─────────────────────────────────────────────────────────────┴──────────────────────────┘

Resource-Limited Setting Simplification: In Level 2 dispensaries and Level 3 health centers where clinical diagnostic testing may be limited, Categories 1 and 2 equate to "YES (Method can be used)", while Categories 3 and 4 equate to "NO (Method should not be used)".

---

2. Combined Hormonal Contraceptives (COCs, Patch & Ring)

Formulations & Mechanism of Action

Combined Oral Contraceptives (COCs) contain a synthetic estrogen (ethinylestradiol, typically 20 to 35 mcg) paired with a synthetic progestin (such as levonorgestrel, desogestrel, or drospirenone).

• Primary Mechanism: Suppression of ovulation. Estrogen suppresses pituitary Follicle-Stimulating Hormone (FSH), preventing dominant follicular development; progestin blunts the mid-cycle Luteinizing Hormone (LH) surge, preventing ovulation.
• Secondary Mechanisms: Progestin thickens cervical mucus into a viscous plug that retards sperm penetration, induces endometrial glandular atrophy preventing blastocyst implantation, and alters tubal motility.

Absolute Contraindications: WHO MEC Category 4

Estrogen stimulates hepatic synthesis of coagulation factors (fibrinogen, factors VII, VIII, X) while decreasing anticoagulant protein S and antithrombin III, substantially elevating the risk of venous and arterial thrombosis. Estrogen also increases hepatic production of angiotensinogen, exacerbating hypertension.

COMBINED ORAL CONTRACEPTIVES: WHO MEC CATEGORY 4 CONTRAINDICATIONS:

1. Cardiovascular & Thromboembolic Disorders:
   • Personal history of, or current, Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
   • Major surgery with prolonged immobilization (bed-bound / orthopedic cast)
   • Known thrombogenic mutations (e.g., Factor V Leiden, Prothrombin G20210A mutation)
   • Personal history of Ischemic Heart Disease (myocardial infarction, angina) or Stroke (TIA / CVA)
   • Severe or uncontrolled hypertension: Systolic BP ≥ 160 mmHg OR Diastolic BP ≥ 110 mmHg
   • Vascular disease associated with diabetes mellitus, or diabetes duration > 20 years

2. Age & Smoking Interaction:
   • Women aged ≥ 35 years who smoke ≥ 15 cigarettes per day
     (Note: Age ≥ 35 years smoking < 15 cigarettes/day is WHO MEC Category 3)

3. Neurological Conditions:
   • Migraine WITH AURA at any age (carries a dramatically multiplied risk of ischemic stroke)
     (Note: Migraine WITHOUT aura in women aged ≥ 35 years is MEC Category 3/4)

4. Hepatic & Malignant Disorders:
   • Active viral hepatitis, severe decompensated cirrhosis, or benign/malignant liver tumors
   • Current or past history of Breast Cancer (hormone-dependent malignancy; Category 4 for all hormonal methods)

5. Postpartum & Lactation Status:
   • Breastfeeding women < 6 WEEKS postpartum (estrogen decreases breast milk quantity/protein content
     and passes into neonatal circulation; thromboembolic risk is also peak in early puerperium)
   • Non-breastfeeding postpartum women < 21 days with other thromboembolic risk factors

Clinical Management of Missed COC Pills

---

3. Progestin-Only Contraceptives

Progestin-only methods do not contain estrogen and therefore do not increase hepatic synthesis of clotting factors or elevate arterial blood pressure. They are exceptionally valuable for women with contraindications to estrogen (e.g., hypertension, history of DVT, migraine with aura, smokers ≥ 35 years) and lactating mothers.

1. Progestin-Only Pills (POPs / "The Minipill")

• Formulations: Micronor (norethisterone 350 mcg), Microval (levonorgestrel 30 mcg), or Cerazette (desogestrel 75 mcg). Taken continuously without hormone-free breaks.
• Mechanism: Thickens cervical mucus within 2 to 4 hours of ingestion; causes endometrial atrophy. (Desogestrel also consistently suppresses ovulation in 97% of cycles).
• Timing Window (Strict Compliance Rule):
  • For traditional POPs (levonorgestrel / norethisterone), contraceptive effect on cervical mucus wanes after 24 hours. A pill is classified as "MISSED" if taken more than 3 HOURS LATE.
  • Management of missed POP (> 3 hours late): Take the late pill immediately, take the next pill at the usual scheduled time, and use barrier contraception (condoms) or abstain for the next 48 HOURS.
  • For desogestrel POPs (Cerazette), the missed pill window is extended to 12 hours.
• Lactation Status: WHO MEC Category 1 (fully acceptable) from 6 weeks postpartum in breastfeeding women, and does not impair milk production.

2. Progestin-Only Injectables (DMPA)

• Formulation: Depot Medroxyprogesterone Acetate (DMPA / Depo-Provera): 150 mg deep intramuscular injection administered into the gluteal or deltoid muscle every 12 weeks (3 months). A subcutaneous version (DMPA-SC / Sayana Press, 104 mg) allows client self-injection.
• Grace Period: Can be administered up to 2 weeks early or up to 4 weeks late (16 weeks from last injection) without requiring backup contraception or pregnancy testing.
• Mechanism: Potently inhibits the pituitary mid-cycle LH surge to consistently suppress ovulation, thickens cervical mucus, and thins the endometrium.
• Clinical Characteristics & Side-Effect Counseling:
  • Menstrual Disruptions: Unscheduled spotting and irregular bleeding are frequent during the first 3 to 6 months. With continued use, amenorrhea occurs in 50% of women at 1 year and over 70% at 2 years. Counseling that amenorrhea is physiologically harmless and beneficial for maternal anemia is crucial to prevent premature method discontinuation.
  • Delayed Return of Fertility: Ovulation does not immediately resume upon injection lapse. The average delay in return of fertility is 9 to 12 months (and up to 18 months) following the last injection due to slow clearance from adipose stores. DMPA is inappropriate for women desiring pregnancy in the near future.
  • Bone Mineral Density (BMD) Loss: DMPA causes a reversible reduction in BMD due to hypoestrogenism. However, bone mass substantially rebounds after discontinuation, and WHO does not recommend restricting DMPA duration in healthy women.
  • Weight Gain: Average gain of 1.5 to 3 kg per year of use due to fluid retention and appetite stimulation.

3. Progestin Subdermal Implants

Implants are long-acting reversible contraceptives (LARCs) providing the highest efficacy of any reversible contraceptive method (failure rate < 0.05%).

• Jadelle: 2-rod system containing 75 mg levonorgestrel per rod (total 150 mg); licensed for 5 years of continuous protection.
• Implanon / Nexplanon: 1-rod system containing 68 mg etonogestrel; licensed for 3 years of continuous protection.
• Mechanism: Suppresses ovulation, thickens cervical mucus, causes endometrial atrophy.
• Rapid Return of Fertility: Blood levels of progestin become undetectable within days of rod removal, with prompt return of normal ovulatory cycles within weeks.
• Primary Side Effect: Irregular, unpredictable spotting or light bleeding (managed with a short 5- to 7-day course of mefenamic acid or low-dose combined oral contraceptives if not contraindicated).

---

4. Intrauterine Devices (IUDs)

1. Copper T 380A Intrauterine Device (Cu-IUD)

• Structure & Lifespan: T-shaped polyethylene frame wound with copper wire (380 mm² surface area). Completely non-hormonal. Licensed for 10 to 12 years of continuous protection.
• Mechanism of Action: Copper ions release continuously into the uterine cavity, inducing a sterile, localized endometrial inflammatory foreign-body reaction with macrophage mobilization. The environment is intensely spermicidal, inhibiting sperm motility, capacitation, acrosome reaction, and viability, preventing fertilization. It does NOT disrupt an established intrauterine pregnancy.
• Side Effects: Increased menstrual flow (menorrhagia) and dysmenorrhea during the initial 3 to 6 months. Treated symptomatically with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs: Ibuprofen 400 mg tds or Mefenamic acid 500 mg tds with meals during menses).

COPPER T 380A IUD: WHO MEC CATEGORY 4 CONTRAINDICATIONS:

1. Active Pelvic Infection:
   • Current, active Pelvic Inflammatory Disease (PID) or purulent cervicitis
   • Puerperal sepsis or immediate post-septic abortion
   • Pelvic tuberculosis with endometrial involvement

2. Anatomical Cavity Distortion:
   • Severe uterine anomalies (bicornuate, septate uterus) or large submucosal leiomyomas
     distorting the uterine cavity (prevents proper fundal seating and increases expulsion risk)

3. Unexplained Vaginal Bleeding:
   • Unexplained abnormal uterine bleeding suspicious for serious pathology prior to clinical evaluation

4. Malignancy & Systemic Disease:
   • Known cervical cancer or endometrial cancer awaiting treatment
   • Wilson's disease or documented severe copper allergy (MEC Category 4 for Cu-IUD only)

Note on Timing of Postpartum Insertion: The Copper IUD can be safely inserted within 48 hours of delivery (post-placental or early puerperal), OR delayed until ≥ 4 weeks postpartum when uterine involution is complete. Insertion between 48 hours and 4 weeks postpartum carries an increased risk of uterine perforation and expulsion (MEC Category 3).

2. Levonorgestrel-Releasing Intrauterine Device (LNG-IUD / Mirena)

• Mechanism: Releases 20 mcg of levonorgestrel daily into the uterine cavity for 5 to 8 years.
• Clinical Indications: In addition to exceptional contraceptive efficacy, the LNG-IUD induces profound local endometrial glandular atrophy, reducing menstrual blood loss by 80% to 90%. It is the established first-line medical therapy for idiopathic heavy menstrual bleeding (menorrhagia), adenomyosis, and endometriosis-associated pelvic pain.

---

5. Emergency Contraception (EC)

Emergency contraception is indicated to prevent unintended pregnancy following unprotected sexual intercourse, contraceptive failure (condom slippage/breakage, missed oral pills), or sexual assault.

EMERGENCY CONTRACEPTION MODALITIES & CLINICAL TIMING:

[1. Oral Levonorgestrel (LNG - Postinor-2 / NorLevo)]
  • Dose: 1.5 mg single dose orally (or two 0.75 mg tablets taken simultaneously)
  • Timing Window: Within 72 HOURS (3 days) of intercourse (can be used up to 120 hours,
    though efficacy declines significantly after 72 hours)
  • Mechanism: Inhibits or delays the LH surge to postpone ovulation; INEFFECTIVE once LH surge has begun
  • Safety: WHO MEC Category 1 across all medical conditions; NOT an abortifacient

[2. Oral Ulipristal Acetate (Ella)]
  • Dose: 30 mg single oral dose
  • Timing Window: Within 120 HOURS (5 days) of intercourse
  • Mechanism: Selective Progesterone Receptor Modulator; can delay follicular rupture even AFTER the LH surge
    has started, maintaining high efficacy throughout the 120-hour window

[3. Copper T 380A IUD (The Gold Standard Emergency Contraceptive)]
  • Procedure: Insertion of a Copper T 380A by a trained provider within 5 DAYS (120 HOURS) of coitus
  • Efficacy: > 99.8% effective (the single most effective emergency contraceptive method available)
  • Advantage: Provides immediate, continuous, long-acting reversible contraception for the next 10 to 12 years

---

6. Permanent Contraceptive Methods

Permanent contraception (voluntary surgical contraception) is indicated for individuals or couples who have achieved their desired family size and desire permanent protection following informed, voluntary consent without coercion.

Bilateral Tubal Ligation (BTL)

• Surgical Approaches:
  • Mini-Laparotomy: Typically performed postpartum through a small 2- to 3-cm infraumbilical transverse incision within 48 hours of delivery (when the uterine fundus is near the umbilicus), or interval via a suprapubic incision.
  • Laparoscopy: Performed as an interval procedure using bipolar electrocoagulation, silastic rings (Falope rings), or titanium clips (Hulka-Clemens / Filshie clips).
• Pomeroy Technique: The standard, most widely utilized mini-laparotomy technique in Kenya. A loop of the mid-ampullary portion of the Fallopian tube is elevated, the base of the loop is ligated with absorbable suture (e.g., 0 or 2-0 chromic catgut or polyglot), and the top of the loop (1 cm segment) is excised. As the absorbable suture dissolves, the two severed, fibrosed ends retract away from each other, preventing recanalization.

Vasectomy (Male Surgical Sterilization)

• Procedure: A minor surgical procedure performed under local infiltration anesthesia. A small scrotal incision or puncture (No-Scalpel Vasectomy technique) is made to isolate the bilateral vas deferens, followed by division, excision of a small segment, and ligation or fascial interposition.
• Post-Procedure Contraception (CRITICAL COUNSELING):
  • Vasectomy is NOT IMMEDIATELY EFFECTIVE.
  • Viable spermatozoa remain stored in the ampullae of the vas deferens and seminal vesicles distal to the surgical transection site.
  • Mandatory Patient Instruction: The couple must continue using an alternative contraceptive method (such as condoms or oral pills) for 3 MONTHS (or approximately 20 ejaculations) following the procedure.
  • Sterility must be confirmed by a post-vasectomy semen analysis showing azoospermia (zero motile sperm) at 12 weeks before abandoning alternative contraception.